Stockreport

ESSA Pharma's Speculative Buy Potential: Masofaniten Promise For Prostate Cancer [Seeking Alpha]

ESSA Pharma Inc.  (EPIX) 
Last essa pharma inc. earnings: 2/13 05:48 pm Check Earnings Report
US:NASDAQ Investor Relations: essapharma.com/investors
PDF Masofaniten has the potential to overcome resistance to other standard-of-care treatments, offering a more effective option for patients with resistant prostate cancer. [Read more]